Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-114
- Development stage
- Unknown
- Lead developer
- Serentrix
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
SER-114 (also known as SER014) is a small molecule antagonist of the transient receptor potential vanilloid-1 (TRPV1) receptor, developed by Serentrix. It is primarily indicated for the treatment of dry eye disease and associated ocular pain and inflammation. TRPV1 is a non-selective cation channel expressed in corneal nerve fibers that responds to inflammatory ligands. SER-114 is specifically designed to block TRPV1 activity while avoiding the hyperthermia adverse events that have historically hindered the development of other TRPV1 antagonists. The compound has demonstrated clinical proof-of-concept in dry eye, pain, and irritable bowel syndrome (IBS), and is considered Phase 2-ready for ophthalmic applications.
02
Targets
Beyond the preview
Go deeper on SER-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-114.